companydirectorylist.com  Global Business Directories and Company Directories
Search Business,Company,Industry :


Country Lists
USA Company Directories
Canada Business Lists
Australia Business Directories
France Company Lists
Italy Company Lists
Spain Company Directories
Switzerland Business Lists
Austria Company Directories
Belgium Business Directories
Hong Kong Company Lists
China Business Lists
Taiwan Company Lists
United Arab Emirates Company Directories


Industry Catalogs
USA Industry Directories














  • Study Details | Multi-centers, Open-Label, Phase 2 Study to Evaluate . . .
    This is a multi-centers, single-arm, open label, Phase 2 clinical trial to evaluate the efficacy and safety of CD7 CAR T cells in subjects with relapsed or refractory T-cell leukemia lymphoma Seventy subjects will be enrolled
  • Efficacy and Safety of Donor-Derived CD7 CAR T Cells for r r T-Cell . . .
    The phase 2 trial was using Bayesian optimal phase 2 (BOP2) design to evaluate the efficacy and safety of the target dose of 1 × 10 6 (±20%) CD7 CAR T cells per kg of body weight in refractory relapsed T-cell acute lymphoblastic leukemia lymphoma (NCT04689659)
  • Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute . . .
    Among 20 patients with r r T-ALL enrolled in this trial, donor-derived CD7 CAR T cells exhibited efficient expansion and achieved a high complete remission rate with manageable safety profile A multicenter, phase II trial of donor-derived CD7 CAR T cells is in progress (NCT04689659)
  • Trial | NCT04689659
    This is a multi-centers, single-arm, open label, Phase 2 clinical trial to evaluate the efficacy and safety of CD7 CAR T cells in subjects with relapsed or refractory T-cell leukemia lymphoma Seventy subjects will be enrolled CD7 CAR T cells will be given once intravenously at one dose (1×106, with an allowance of ± 20%) in patients received previous HSCT donor-derived CAR T cells
  • Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and . . .
    At the 2022 ASH, the PAN team presented an interim report from the Phase II clinical trial of donor-derived CD7 CAR T-cells for the treatment of R R T-cell acute lymphoblastic leukemia lymphoma (NCT04689659) (68)
  • Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and . . .
    This is a multi-centers, single-arm, open label, Phase 2 clinical trial to evaluate the efficacy and safety of CD7 CAR T cells in subjects with relapsed or refractory T-cell leukemia lymphoma Seventy subjects will be enrolled CD7 CAR T cells will be given once intravenously at one dose (1×106, with an allowance of ± 20%) in patients received previous HSCT donor-derived CAR T cells
  • Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute . . .
    Among 20 patients with r r T-ALL enrolled in this trial, donor-derived CD7 CAR T cells exhibited efficient expansion and achieved a high complete remission rate with manageable safety profile A multicenter, phase II trial of donor-derived CD7 CAR T cells is in progress (NCT04689659)
  • Chimeric antigen receptor T cell treatment in Relapse . . . - ICH GCP
    Clinical Trial NCT04689659 Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia Lymphoma




Business Directories,Company Directories
Business Directories,Company Directories copyright ©2005-2012 
disclaimer